CliffBio
small molecule

CARBOPROST TROMETHAMINE

CARBOPROST TROMETHAMINE

Loss of exclusivity—loss of exclusivity
CompanyLong Grove →See this company's full patent-cliff portfolio

Drug detail

Brand nameCARBOPROST TROMETHAMINE
Active ingredientCARBOPROST TROMETHAMINE
StrengthEQ 0.25MG BASE/ML
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalAugust 2022
Marketing statusRX

More from Long Grove

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

CARBOPROST TROMETHAMINE patent cliff — loss of exclusivity — | CliffBio